OyaGen, Inc.
Rochester
New York
United States
4 articles about OyaGen, Inc.
-
OyaGen, Inc. announces a new publication for its COVID therapeutic in development and publication of related patents
9/18/2023
OyaGen, Inc. Today the company announced publication in Antiviral Research of studies evaluating the mechanism of action of its proprietary COVID therapeutic in preclinical development.
-
The companies also plan to develop the candidate for the treatment of other potential future viral diseases.
-
Oyagen, Inc. Publishes Study On Its OYA1 As A "Highly Effective" Experimental Drug Candidate For Treating Infections By The Ebola Virus
1/7/2021
OyaGen, Inc. announced publication in VIRUSES, a peer reviewed journal, of studies carried out by OyaGen in collaboration with NIH/NIAID Integrated Research Facility at Fort Detrick MD.
-
OyaGen, Inc. Announces a Compound in Development with Broad Antiviral Activity Against Coronaviruses, including SARS-CoV-2
3/11/2020
OyaGen, Inc. announced today new unpublished results from collaborative research with the National Institute of Allergy and Infectious Diseases' Integrated Research Facility at Fort Detrick, MD